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This study investigates the role of the proviral transcriptional enhancer for B-lymphoma induction by exogenous Akv murine leukemia virus.
Infection of newborn inbred NMRI mice with Akv induced 35% plasma cell proliferations (PCPs) (consistent with plasmacytoma), 33% diffuse
large B-cell lymphomas, 25% follicular B-cell lymphomas and few splenic marginal zone and small B-cell lymphomas. Deleting one copy of the
99-bp proviral enhancer sequence still allowed induction of multiple B-cell tumor types, although PCPs dominated (77%). Additional mutation of
binding sites for the glucocorticoid receptor, Ets, Runx, or basic helix–loop–helix transcription factors in the proviral U3 region, however, shifted
disease induction to almost exclusively PCPs, but had no major influence on tumor latency periods. Southern analysis of immunoglobulin
rearrangements and ecotropic provirus integration patterns showed that many of the tumors/cell proliferations induced by each virus were
polyclonal. Our results indicate that enhancer mutations weaken the ability of Akv to induce mature B-cell lymphomas prior to the plasma cell
stage, whereas development of plasma cell proliferations is less dependent of viral enhancer strength.
© 2006 Elsevier Inc. All rights reserved.Keywords: Akv; Murine leukemia virus; B-cell lymphoma; Plasmacytoma; Retrovirus; Lymphomagenesis; Mouse tumor model; Transcriptional enhancerIntroduction
While several studies report on B-lymphoma induction in
mice linked to the replication of murine leukemia viruses
(MLVs) and proviral insertional mutagenesis, these models are
mostly based upon the spontaneous activation of Akv-like
endogenous ecotropic retroviruses (Gilbert et al., 1993; HartleyAbbreviations: PCP, plasma cell proliferation; LCC, large cell components;
DLBCL, diffuse large B-cell lymphoma; FBL, follicular B-cell lymphoma;
SMZL, splenic marginal zone lymphoma; SBL, small B-cell lymphoma; ML,
myeloid leukemia with maturation; preT-LBL, pre-T-cell lymphoblastic
lymphoma.
⁎ Corresponding author. Fax: +45 8619 6500.
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doi:10.1016/j.virol.2006.12.016et al., 2000; Mucenski et al., 1986). We have previously
reported that both Akv MLV and a derivative (Akv1–99) with
just one copy of the 99-bp proviral enhancer induce various
forms of mature B-cell lymphomas with high incidence and
mean latencies of 1 year after injection of newborn random-bred
NMRI mice, which are free of endogenous ecotropic MLVs
(Lovmand et al., 1998). In a further development, we found that
neonatal inoculation of an inbred NMRI strain with wildtype or
nuclear factor 1 (NF1) site enhancer mutants of Akv1–99
resulted in an expansion of cells with characteristics of plasma
cells (classified as plasmacytomas and plasma cell prolifera-
tions), through a disease process that we proposed may involve
an antigen-stimulatory component (Sørensen et al., 2005). With
a mean latency of only 6 months (Sørensen et al., 2005), this is
the most rapid murine B-lymphoma model using non-acutely
transforming retroviruses.
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potency of many MLVs have been mapped to the proviral U3
enhancer and, in some instances, to specific transcription factor
binding sites in this region (Hallberg et al., 1991; Lenz et al.,
1984; Nieves et al., 1997; Speck et al., 1990). In contrast, the
viral genetic determinants of B-cell tumor induction by Akv/
Akv1–99 are not well-characterized, although we have reported
that two NF1 binding sites in the proviral enhancer are
dispensable for tumor induction by Akv1–99 in inbred NMRI
mice (Sørensen et al., 2005). This study is based on the
hypothesis that other binding sites in the U3 promoter/enhancer
region may play a significant role in Akv/Akv1–99-induced
oncogenesis in vivo.
The 99-bp Akv enhancer contains binding motifs for Ets
(LVb), Runx (AML/CBF) and basic helix–loop–helix (bHLH)
transcription factors. The enhancer bHLH site (Egre) overlaps
with a glucocorticoid response element (GRE), which mediates
dexamethasone-induced activation of viral gene expression in
cell culture (Celander et al., 1988). A second bHLH site (named
Ea/s, also present in SL3-3) is located approximately 60 bp
downstream of the enhancer. Mutating the Egre and/or Ea/s site(s)
reduces Akv and Akv1–99 enhancer activity significantly in
lymphoid cell lines (Nielsen et al., 1994; Nielsen et al., 1996).
The Ets, Egre and GRE sites in the Akv/Akv1–99 enhancer are
identical to the equivalent motifs in the closely related, and more
extensively studied T-cell lymphomagenic viruses SL3-3 and
MoMLV,whereas the Runx (core) site sequences of these viruses
have a single nucleotide difference (Golemis et al., 1990).
Mutation of any of these sites impedes tumor induction by
MoMLV considerably, and for the Runx and Ets (LVb) sites also
causes a partial shift in disease specificity (Speck et al., 1990).
Likewise, efficient T-lymphoma induction by SL3-3 requires
intact enhancer Runx sites (Ethelberg et al., 1997b; Hallberg et
al., 1991; Morrison et al., 1995; Sørensen et al., 2004), whereas
the Ets site is of minor importance (Nieves et al., 1997).
These findings together with the scarcity of reports of B-cell
tumor induction by exogenous non-oncogene-bearing ecotropic
MLVs (Lovmand et al., 1998; Sørensen et al., 2005) prompted us
to investigate the oncogenic properties of several Akv-derived
viruses in continuation of our earlier analysis of Akv1–99 NF1
site mutants (Sørensen et al., 2005). We here included the
wildtype Akv virus with both copies of the 99-bp repeat as well
as nine new Akv1–99 transcription control mutants in inbred
NMRI mice. Five different binding sites (Runx, Ets, Egre, GRE
and Ea/s) in the enhancer–promoter region of Akv1–99 were
mutated individually or in different pairs. The current work is the
first to address the possible role(s) in Akv1–99 pathogenicity of
these five transcription factor binding sites, which except for Ea/s
are highly conserved elements of the prototypic MLV enhancer
framework (Golemis et al., 1990).
Results
Generation of mutant viruses
Point mutations were introduced into each of five different
transcription factor binding sites (Ets, Runx, GRE, Egre and Ea/s)in the U3 region of Akv1–99 MLV (Fig. 1A) to investigate the
possible role of these sites in viral pathogenesis. In some
cases, two sites were mutated simultaneously (Runx+GRE,
Runx+Egre, GRE+Ea/s, Egre+Ea/s). This study used Akv1–99
rather than Akv because viral enhancer activity at least in some
cases is more severely affected by single site mutations when
one 99-bp repeat is deleted (Nielsen et al., 1996). Also,
structural LTR changes by copy number fluctuation are less
likely to arise in vivo during the replication of a single-copy
enhancer containing virus (Lovmand et al., 1998; Sørensen et
al., 2005). To examine the effect of the mutations on Akv1–99
enhancer activity, transient expression levels of a chloramphe-
nicol acetyltransferase (CAT) reporter gene driven by wildtype
or mutated U3 regions of Akv1–99 were measured in MPC11
murine plasmacytoma B cells, NALM6 human pre-B cells,
L691 murine T cells and NIH 3T3 murine fibroblasts (Fig. 1B,
Table 1). Each single site mutation (mEts, mRunx, mGR, mEgre
or mEa/s) reduced transient expression significantly (1.5- to 5-
fold) in all four cell lines, clearly demonstrating that viral
enhancer activity is compromised by the specific mutation
used. The relative contribution of each site to Akv1–99
enhancer strength varied slightly between the cell lines. In some
cases, mutation of two sites decreased expression even further
(mRunx+mEgre and mEgre+mEa/s in MPC11, NALM6 and
NIH 3T3 cells), but such an effect was not always detected.
Reduced enhancer strengths for Akv1–99 E-box mutants have
been reported in an earlier study using a single nucleotide
substitution in the Egre and Ea/s site and a slightly different
panel of hematopoietic cell lines (Nielsen et al., 1996). We have
previously reported that the deletion of one 99-bp enhancer
copy reduces transient enhancer activity ∼2-fold in NIH 3T3
and NALM6 cells, causes a 2-fold increase in L691 cells, but
has no effect in MPC11 cells (Lovmand et al., 1998; Sørensen
et al., 2005).
Tumor induction in inbred NMRI mice
To investigate the lymphomagenic properties of Akv, Akv1–
99 and the nine Akv1–99 binding site mutants, newborn inbred
NMRI mice were injected with equal amounts of infectious
virus particles. Control mice were mock-injected with complete
medium. All viruses induced tumors with similar incidence and
mean latency periods of 5 to 7 months (Table 2 and Fig. 2).
Gross pathology revealed no major differences between the
viruses; the infected mice presented with enlarged spleen and
enlarged lymph node(s). The thymus was generally not
enlarged. In control mice, spontaneous tumor development
was rare (Table 2).
Akv and Akv1–99 showed strikingly similar mean tumor
latencies in the inbred NMRI strain (Table 2 and Fig. 2), similar
to our previous results in random-bred NMRI mice (Lovmand et
al., 1998). Mutation of the Ets motif had no effect on viral tumor
latency, whereas five of the mutants (1–99mRunx, 1–99mGR,
1–99mEgre, 1–99mEa/s and 1–99mRunx+mGR) induced
tumors with moderately, yet significantly shorter mean latency
than Akv1–99 (Table 2 and Fig. 2). Although 1–99mRunx+mEgre
was the only virus with significantly extended tumor latency
Fig. 1. (A) Proviral enhancer structures of Akv and Akv1–99 MLV. Akv contains two direct copies of a 99-bp enhancer sequence, whereas one copy has been deleted
in the U3 region of Akv1–99. The complete 99-bp nucleotide sequence with indications of binding site motifs for cellular transcription factors is also given: NF1
(nuclear factor 1), Ets, Runx (core), GRE (glucocorticoid response element) and Egre (E-box, bHLH/basic helix–loop–helix site). An additional E-box site (Ea/s) is
present in the U3 region downstream of the enhancer. Specific point mutations used to generate nine different Akv1–99 transcription control mutants (1–99mEts, 1–
99mRunx, 1–99mGR, 1–99mEgre, 1–99mEa/s, 1–99mRunx+mGR, 1–99mGR+mEgre, 1–99mGR+mEa/s and 1–99mEgre+mEa/s) are indicated at the bottom. The
Ets core consensus binding sequence (GGAA/T (Sementchenko and Watson, 2000)) was disrupted by a GG to TT substitution, originally used by others to mutate the
equivalent site (LVb) in MoMLV (Speck et al., 1990). The 3-bp TGG Runx site mutation abolishes DNA–protein complex formation in vitro (Thornell et al., 1988,
1991), as exploited in previous studies of SL3-3 MLV (Ethelberg et al., 1997b; Hallberg et al., 1991; Sørensen et al., 2004). A 1-bp change CAGATG to AAGATG in
Egre eliminates in vitro binding of class A bHLH factors, transactivation in vivo and dexamethasone-induced activation via glucocorticoid receptor (GR) binding to
GRE (Nielsen et al., 1994, 1996), however, two addition alterations were introduced into Egre and Ea/s (CAGATG to ACGACG) in this study to avoid reversion in vivo
by a single point mutation. The Egre site mutation also interrupts GRE (consensus sequence: AGAACA(N)3TGTTCT (Beato et al., 1995)), while the GA to CG
mutation in GRE is positioned upstream of the Egre site consensus sequence (E-box: CANNTG (Massari and Murre, 2000)). Primers used for PCR amplification of
proviral U3 regions are shown at the top. (B) Outline of the chloramphenicol acetyltransferase (CAT) reporter construct used. CAT expression is driven by a complete
proviral LTR, which in the example shown has the structure of Akv1–99.
181K.D. Sørensen et al. / Virology 362 (2007) 179–191compared to Akv1–99, all double mutants induced tumors with
shorter mean latency than their corresponding single site
mutants (significant in all cases, except 1–99 mRunx+mGR)
(Table 2). The present findings for Akv/Akv1–99, with none of
the mutations having a major influence on mean tumor
latencies, contrast the highly debilitating effects on viral
oncogenicity reported for certain enhancer mutants of closely
related T-lymphomagenic viruses SL3-3 and MoMLV (Ethel-
berg et al., 1997b; Hallberg et al., 1991; Morrison et al., 1995;
Nieves et al., 1997; Speck et al., 1990; Sørensen et al., 2004).We note that small differences in tumor induction may be
hidden by the short mean latencies measured in inbred NMRI
mice.
Preservation of point mutations in proviral U3 regions
amplified from genomic tumor DNA
The effect on viral pathogenicity of introduced point
mutations can be counteracted by reversion or suppressor
mutations arising during tumor induction in vivo. To test this
Table 1
Transient transfection assays with CAT reporter constructs
Enhancer variant Relative CAT activity (SD) a
MPC11 NALM6 L691 NIH 3T3
Akv1–99 100 100 100 100
1–99 mEts 37 (18) 22 (2) 25 (8) 19 (5)
1–99 mRunx 37 (13) 28 (1) 28 (5) 19 (15)
1–99 mGR 49 (6) 68 (3) 30 (1) 56 (15)
1–99 mEgre 51 (5) 32 (5) 25 (2) 31 (13)
1–99 mEa/s 40 (3) 44 (7) 35* 26 (3)
1–99 mRunx+mGR 35 (14) 34 (8) 44* 25 (2)
1–99 mRunx+mEgre 8 (6) 10 (1) 40* 5 (2)
1–99 mGR+mEa/s ND ND ND 24 (14)
1–99 mEgre+mEa/s 14 (6) 10 (1) 44* 7 (1)
a Average CAT activities were normalized to the activity of pAkv1–99cat,
which was arbitrarily set to 100. Standard deviations of 2–8 independent
transfections, all performed in duplicate, are given. A few transfections were
performed only once and are marked by asterisks. ND, not determined.
182 K.D. Sørensen et al. / Virology 362 (2007) 179–191possibility, proviral U3 regions were PCR amplified in bulk
from genomic tumor DNA samples from 198 mice, equally
representing all viruses. In most cases (mice infected with Akv,
Akv1–99 and Akv1–99 mutants with an intact Ea/s site),
proviral U3 sequences were amplified with a primer (440) in the
5′ end of the U3 region and a primer (2620) located ca. 60 bp
downstream of the enhancer (i.e. overlapping the Ea/s site) (Fig.
1A). Amplification products were sequenced from position 42
to 260/359 (Akv1–99/Akv) of the proviral LTR. In cases having
the Ea/s site mutated (1–99mEa/s, 1–99mGR+mEa/s and
1–99mEgre+mEa/s), primer 440 was used instead with a primerTable 2
Tumor induction in inbred NMRI mice
Virus Tumor incidence a Mean tumor
latency in days (SD)
Akv 40/40 (100%) 184 (26)
Akv1–99 49/50 (98%) 180 (23)
1–99 mEts 43/44 (98%) 182 (27)
1–99 mRunx 37/39 (95%) 149 (22) e
1–99 mGR 40/41 (98%) 145 (28) e
1–99 mEgre 41/42 (98%) 160 (27)
e
1–99 mEa/s 47/47 (100%) 165 (23)
e
1–99 mRunx+mGR 47/48 (98%) 160 (29) e
1–99 mRunx+mEgre 45/46 (98%) 199 (35)
e, h
1–99 mGR+mEa/s 46/49 (94%) 186 (26)
h
1–99 mEgre+mEa/s 41/41 (100%) 183 (38)
h
Mock j 1/29 (3%) –
a Number of mice with tumor development (diagnosed on the basis of significant
b As determined by Southern blotting analysis using T-cell receptor β, immunoglo
tumors with clonal rearrangements/number of tumors investigated). nd, not determin
c As defined by the detection of clonal IgH and/or Igκ rearrangements by Southern
of the Ig loci.
d This tumor also had IgH and Igκ clonally rearranged, but was not further analy
e Significantly different from Akv1–99 (p<0.05; log-rank test).
f One thymic tumor developed relatively fast (107 days) and had TCRβ-J2 but
examination was not performed in this case.
g One thymic tumor had TCRβ-J1, -J2 and IgH, but not Igκ clonally rearranged.
h Significantly different from both of the corresponding single site mutants (p<0.
i These cases also had clonal Igκ but not TCRβ-J1 rearrangements.
j Two control groups, C1 and C2, with 15 and 14 mice, respectively, were comb
enlargement of the spleen and mediastinal lymph nodes, indicative of lymphoma, w(1112akv) in the 5′ UTR (Fig. 1A). Nucleotide sequences of the
resulting amplicons were determined from position 42 to the
end of the U3 region (nt 383, Akv1–99). The two primer sets
did not amplify endogenous sequences from non-infected
control mice (data not shown).
Samples from Akv-induced tumors consistently (22 out of 22
tumors) produced two bands of the respective sizes predicted for
Akv with two copies of the 99-bp enhancer (376 bp) or with one
complete 99-bp repeat deleted (277 bp) (data not shown), as we
later verified by sequencing. DNA samples from wildtype and
mutant Akv1–99-induced tumors gave only a single PCR band
(176 of 176 tumors) corresponding to the size expected for a one-
copy 99-bp enhancer containing virus (277 bp/644 bp dependent
on primer usage) (data not shown). Sequencing of the amplified
proviral U3 regions showed that the introduced point mutations
were maintained in all cases. Akv and Akv1–99 virus sequences
also had not changed and no second-site mutations were
detected. Repeat gain(s) were not observed in any of the 198
cases. The consistent conservation of point mutations in the Ets,
Runx, Egre, GRE and Ea/s motifs in proviruses from tumor DNA
correlates well with the moderate effects of these mutations on
viral tumor latency periods (Table 2).
Distinct disease induction patterns of Akv and Akv1–99
Histopathological examination revealed marked phenotypic
differences in tumor induction by Akv and Akv1–99 in inbred
NMRI. Akv induced three main tumor types: 35% plasma cell
proliferations, 33% diffuse large B-cell lymphoma (DLBCL)DNA rearrangements b Incidence of clonal
B-cell lymphoma c
Igκ IgH TCRβ-J1 TCRβ-J2
7/26 7/20 0/27 0/26 9/27 (33%)
9/33 4/22 1/32 1/22 11/35 (31%)
8/16 5/11 0/17 1/16 d 9/16 (56%)
2/22 2/17 0/10 0/19 4/22 (18%)
5/23 1/9 0/9 1/22 f 5/23 (22%)
5/20 4/19 0/6 0/22 7/20 (35%)
7/19 5/10 g 1/18 g 1/22 g 7/19 (37%)
4/10 4/10 0/10 0/10 4/10 (40%)
6/14 nd 0/17 3/20 i 6/14 (43%)
3/10 2/10 0/10 0/10 3/10 (30%)
4/10 3/10 0/10 0/10 4/10 (40%)
– – – – –
ly enlarged lymphoid organs)/number of mice injected (percentage).
bulin heavy and kappa light chain gene specific hybridization probes (number of
ed.
analysis of genomic tumor DNA. In some cases, data were available for only one
zed.
not Igκ clonally rearranged, indicating a T-lineage origin. Histopathological
It was histologically diagnosed as a pre-T-cell lymphoblastic lymphoma.
05; log-rank test).
ined. They were sacrificed at 246 (C1) and 300 (C2) days of age. In group C1
as observed in one mouse at day 246.
Fig. 2. Pathogenicity in inbred NMRI mice. The curves show cumulative incidences of tumor development versus the number of days after injection of infectious virus
particles into newborn mice.
183K.D. Sørensen et al. / Virology 362 (2007) 179–191and 23% follicular B-cell lymphoma (FBL). A few cases of
splenic marginal zone lymphoma (SMZL) and small B-cell
lymphoma (SBL) were also seen (Table 3). In this study, as well
as in our previous work (Sørensen et al., 2005), the term plasma
cell proliferation (PCP) refers to a histopathologically homo-
geneous disease entity, which at the molecular level represented
a continuum ranging from polyclonal plasma cell proliferation
to oligo-/monoclonal malignant plasma cell lymphoma, i.e.
plasmacytoma (see below).
Although Akv1–99 retained the capacity to induce multiple
B-cell tumor types, disease induction was strongly shifted
towards PCP (77%) (Table 3). This shift was also highlighted by
the finding of mixed tumors (PCP plus DLBCL, FBL, SMZL or
SBL) in seven Akv1–99 infected mice (Table 3). Akv1–99
induced DLBCL in 19% of the mice in the present work, but
only plasma cell proliferations (including plasmacytomas) were
observed in our previous study (Sørensen et al., 2005). This
discrepancy might be explained by the lower number of tumors
examined histopathologically in the former work (Sørensen et
al., 2005). One mouse infected with Akv1–99 developed a pre-
T-cell lymphoblastic lymphoma. Thymus, spleen, cervical and
mesenteric lymph nodes were markedly enlarged and diffusely
infiltrated by a monotonous population of CD3 and TdT
positive blastic cells (data not shown).
Infiltrated lymph nodes in mice with PCP showed partial
effacement of the architecture with the presence of hyperplastic
germinal centers lacking the mantle zone (so-called “naked”
germinal centers), surrounded by a diffuse proliferation of
medium-sized plasma cells with a monotonous appearance. In a
few cases, the thymus was also infiltrated (Figs. 3A–C).
Immunohistochemically, the plasma cells were CD79acy and
CD138 positive (Fig. 3D, and data not shown). The prolifera-
tion rate was generally low, as judged from Ki-67 staining (data
not shown). Plasma cell infiltration in the spleen was found
primarily around the white pulp and in the red pulp, and in
severe cases, naked germinal centers were also found (data notshown). About 70% of the Akv- and 25% of the Akv1–99-
induced PCPs contained mature plasma cells intermingled with
large B cells or centroblasts (Figs. 3E–F), which stained
positive for B220/CD45R, but not for CD138 (Fig. 3G, and
data not shown). This tumor phenotype, which we refer to as
PCP with large cell components (LCC) (Table 3), has not
previously been described in mice. It showed marked
morphological similarity to polymorphic post-transplant lym-
phoproliferative disorders in man, which are known to be
antigen-driven (Jaffe et al., 2001; Lacasce, 2006). Hence, these
cases may represent tumor progression. Southern analysis
revealed no difference in Ig clonality between PCPs with and
without LCC (Table 3).
DLBCLs were characterized by a diffuse infiltration of large
blastic cells (Figs. 3H–I), predominantly in the white pulp of the
spleen (data not shown). Partial involvement of the lymph
nodes was observed in some cases (Figs. 3G–H). The liver was
infiltrated in all cases (mainly in the portal areas) by nodules
composed primarily of B220/CD45R and CD79acy positive
large blastic cells, intermingled with reactive lymphocytes,
granulocytes, eosinophils and histiocytes (Fig. 3J, and data not
shown). In FBLs, the neoplastic cells stained positive for B220/
CD45R and CD79acy and infiltrated the lymph nodes in a
diffuse pattern, and less frequently the spleen. The neoplastic
population was composed of a mixed population of centroblasts
and centrocytes (Fig. 3K). The proliferation rate was high, as
shown by Ki-67 staining (Fig. 5L).
Mice with SMZL showed severe splenomegaly. In all cases,
the lymphoma was confined to the spleen. The red pulp was
infiltrated by a monotonous population of medium-sized cells
with abundant pale cytoplasm, central nucleus and fine
chromatin. The phenotype of SMZL was unique in that the
neoplastic cells were positive for CD79acy and in most cases
negative for B220/CD45R (not shown). SBL was associated
with splenomegaly and diffuse infiltration of lymphoid and non-
lymphoid tissues by small, CD79acy positive B cells with scant
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184 K.D. Sørensen et al. / Virology 362 (2007) 179–191cytoplasm, condensed chromatin and inconspicuous nuclei (not
shown).
In contrast to these clearly different disease induction
patterns of Akv and Akv1–99 in inbred NMRI mice, our
former work showed similar lymphomagenic properties of the
two viruses in random-bred NMRI mice with predominant
induction of DLBCLs and B-cell lymphoblastic lymphomas,
and no plasmacytomas (Lovmand et al., 1998 and unpublished).
Hence, different mechanisms of viral disease induction may
exist in inbred and random-bred NMRI mice.
Restricted tumor induction by Akv1–99 mutants
The nine Akv1–99mutants induced almost exclusively PCPs
(90–100%) (Table 3). Notably, all of the mutants had lost the
ability to induce DLBCL. Other tumor types, including FBL,
SMZL, myeloid leukemia with maturation and pre-T-cell
lymphoblastic lymphoma,were seen in some of themutant series
(1–99mEts, 1–99mGR, 1–99mEgre, 1–99mEa/s, 1–99mRunx
+mGR, 1–99mRunx+mEgre, 1–99mGR+mEa/s), however,
these caseswere rare andmostly identified inmice alsodiagnosed
with PCP (Table 3 and data not shown). In the three mice with
myeloid leukemia, the spleen was infiltrated by more than 20%
myeloblasts (positive for myeloperoxidase) and granulocytes in
all maturation stages (not shown).
The ratio of PCP with or without LCC (Table 3) as well
as the incidence of detectable clonal immunoglobulin
rearrangements by Southern blotting analysis (Table 2 and
see below) showed considerable variation between the nine
mutant series. We found no simple correlation between these
measures, but note that 1–99mEts-infected mice presented
with both the highest fraction of PCP with LCC (32/41) and
the highest incidence of clonal B-cell lymphoma (56%),
whereas the lowest incidence of PCP with LCC (0/10) and
clonal B-cell lymphoma (18%) was seen in 1–99mRunx-
infected mice (Tables 2 and 3). Furthermore, the two double
mutants with the Runx site mutated (1–99mRunx+mGR and
1–99mRunx+mEgre) induced the second and third lowest
incidences of PCP with LCC (Table 3), altogether suggesting
that out of the five binding sites investigated, the Runx site
contributes most strongly and the Ets site most weakly to
Akv1–99 oncogenic potency. A comparison of the pheno-
typic disease patterns induced by all Akv viruses in this
study (Table 3) suggests that viral enhancer strength is
important for induction of the mature B-lymphoma types
DLBCL and FBL, while this is not needed for induction of
plasma cell proliferations.
Molecular tumor analysis
For further characterization, Southern blotting analysis of
genomic tumor DNAwas performed using hybridization probes
specific for the immunoglobulin kappa light chain (Igκ), the
immunoglobulin heavy chain (IgH) and the T-cell receptor β
(TCRβ) loci (Fig. 4). Clonal TCRβ rearrangements were
detected in only a few samples (7 out of 199) (Table 2; Figs. 4A,
C), consistent with the histological finding of mainly B-cell
Fig. 3. Histopathological and immunohistological analysis of tumor tissues. Enlarged lymph nodes, spleen and thymus from retrovirus-infected inbred NMRI mice.
(A–D) Plasma cell proliferation. (A) Section of thymus showing a monotonous proliferation of plasma cells surrounding a “naked” germinal center (indicated by
arrows) (H&E). (B) Lymph node with a monotonous proliferation of medium-sized plasma cells with abundant cytoplasm. (C) A higher magnification demonstrates
the presence of abundant Russell bodies (arrows), which are plasma cells with abundant immunoglobulins in the cytoplasm (H&E). (D) Plasma cells are positive for
CD79acy (IHC, lymph node). (E–F) Plasma cell proliferation with a large cell component. (E) Lymph node infiltrated with a mixture of medium-sized plasma cells
(short arrow) and larger lymphoid cells (large arrow), which have irregular nuclei, blastic chromatin, one to three eosinophilic nucleoli and abundant pale cytoplasm
(H&E). (F) Another field reveals the presence of mitotic figures (large arrow) and Russell bodies (short arrows) (H&E). (G–J) Diffuse large B-cell lymphoma
(DLBCL). (G) Lymph node partially infiltrated by a B-cell lymphoma. Note that the tumor cells are B220 positive (IHC). (H) Lymph node diffusely infiltrated by large
centroblastic cells with blastic chromatin and prominent nucleoli (arrows) (H&E). (I) Spleen infiltrated by large lymphoid cells with blastic chromatin, one big central
nucleolus and abundant cytoplasm characteristic of immunoblastic lymphoma (H&E). (J) Liver infiltrated by a DLBCL positive for B220 (IHC). (K–L) Lymph node
with murine follicular B-cell lymphoma. (K) The tumor population is composed of small and large cleaved and non-cleaved germinal center cells (H&E). (L) Note the
high proliferation rate of the tumor demonstrated with the proliferation marker Ki-67 (IHC).
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186 K.D. Sørensen et al. / Virology 362 (2007) 179–191tumor induction. Three mice infected with Akv1–99 (Fig. 4A,
lane 5), 1–99mGR or 1–99mEa/s had TCRβ but not Igκ
clonally rearranged (Table 2). Histologically, two of these were
pre-T-cell lymphoblastic lymphomas, one was not analyzed
(1–99mGR). Four mice (one infected with 1–99mEts, three
with 1–99mRunx+mEgre) had TCRβ and Igκ clonally rear-
ranged (Table 2). These cases were histologically diagnosed as
plasma cell proliferations.
One third of the mice infected with Akv or Akv1–99 had
detectable Ig rearrangements, whereas the incidence varied
from 18% to 56% in the mutant-infected mice (Table 2; Figs.Fig. 4. Southern blotting analysis of virus-induced tumors. Representative results o
1–99mRunx (D–E). Genomic tumor DNA samples were cut with HindIII (A, C, D),
TCRβ-J1, TCRβ-J2 or ecotropic env gene-specific probe as indicated. Numbers abo
DNA from non-infected inbred NMRI mice; lane B, genomic liver DNA from Balb/c m
by arrow heads. One Akv1–99-induced tumor (A, lane 5), histologically diagnosed as
two distinct bands with the env hybridization probe indicated the presence of two clo4A, C). No consistent correlation was seen by comparing single
site to matching double site mutated viruses, raising the
possibility that some of the variation may be stochastic. In
some cases, clonal rearrangements were detected by Southern
analysis in only one of the Ig loci. There was no morphological
evidence for a pre-B-cell lymphoma in the tumors having IgH
but not Igκ clonally rearranged.
Hybridization with an ecotropic env gene-specific probe
to Southern blots of tumor DNA digested with HindIII (no
cutting sites in Akv/Akv1–99) gave a smear rather than
distinct band(s) in the vast majority of cases (Figs. 4A, C–btained from tumors induced by Akv1–99 (A–B), 1–99mEgre+mEa/s (C) and
PstI (B) or EcoRV (E), transferred to nylon membranes and hybridized with Igκ,
ve each lane indicate individual tumors analyzed for each virus; lane C, control
ouse harboring one endogenous ecotropic provirus. Germline bands are marked
a pre-B-cell lymphoma, had TCR-β but not Igκ clonally rearranged. Detection of
nal ecotropic provirus integrations in this tumor (A, bottom panel, lane 5).
187K.D. Sørensen et al. / Virology 362 (2007) 179–191D; and data not shown), indicating that most of the virus-
induced tumors in inbred NMRI are oligo- or polyclonal
with respect to provirus integrations. The low incidences of
clonal Ig rearrangements (Table 3) may therefore be due to
low tumor clonality. The presence of integrated ecotropic
proviruses in the tumors was demonstrated by Southern
hybridization to an approximately 8-kb internal env-contain-
ing provirus fragment generated by PstI or EcoRV digestion
of genomic tumor DNA (Figs. 4B, E). Finally, we note that
the phenotypic disease patterns of all viruses (Table 3) were
the same if only the cases with detectable clonal Ig
rearrangements were included in the comparison (data not
shown).
Discussion
In the present study, we have undertaken a systematic
analysis of disease induction by exogenous Akv, Akv1–99 and
additional enhancer mutants. To address the role of the
transcriptional enhancer, we chose to mutate sites of the
enhancer framework associated with disease induction by T-
lymphomagenic viruses, including binding sites for factors of
the Runx and Ets families as well as E-box motifs and a GRE
site overlapping one of the E-box motifs (Speck et al., 1990;
Zaiman and Lenz, 1996; Zaiman et al., 1998). The mutations in
all cases reduced viral enhancer strength in the lymphoid and
fibroblast cell lines used for transient expression analysis. To
unveil possible differences in induction of multiple diseases
between the viruses, we used larger animal cohorts than in our
previous studies (Lovmand et al., 1998; Sørensen et al., 2005).
As discussed below, the main results of the present work are: (1)
all viruses induce tumors of the B-cell lineage, (2) many tumors
of all groups are polyclonal and (3) enhancer mutations inhibit
induction of mature B-cell lymphomas (DLBCL and FBL) and
shift tumor induction towards the fully differentiated plasma
cell stage.
Using inbred NMRI mice, we found that Akv, Akv1–99
and all Akv1–99 enhancer mutants induced lymphomas or
other lymphoproliferative diseases in the B-cell compartment
with nearly 100% incidence and mean latencies of 5 to
7 months. For all viruses, clonal or oligoclonal B-cell
expansions were detected in some but not all animals by
Southern analysis of immunoglobulin rearrangements. This
Southern pattern resembles that previously observed for
Akv1–99 and Akv1–99 NF1 site mutants in this mouse strain
(Sørensen et al., 2005). Moreover, several independent tumors
of the present study displayed rearranged Ig fragments of
similar sizes (Fig. 4, and not shown), as also noted in our
former work on wildtype and NF1 site mutated Akv1–99
(Sørensen et al., 2005). This is, however, clearly distinct from
the prominent Ig rearrangement patterns with bands of diverse
sizes reported for both Akv and Akv1–99-induced tumors in
random-bred NMRI mice (Lovmand et al., 1998). Although
co-migration of fragments does not prove identity, it may
suggest that the repertoire of Ig rearrangements is restricted in
the B-cell tumors of inbred NMRI mice, irrespectively of the
virus mutant used.These observations extend our previous suggestion that B-
cell lymphoma induction by Akv viruses in the inbred NMRI
mouse strain may involve an immunostimulatory component
(Sørensen et al., 2005). Such stimulation may cause a
polyclonal expansion of B cells early during infection as well
as chronic antigen-specific stimulation of individual clones at
later stages of the disease. Although the animals are infected just
after birth to avoid a neutralizing immune response, it is
conceivable that this state of tolerance involves signaling in the
innate and specific immune response (Sarzotti et al., 1996). For
example, it is now recognized that retroviruses may activate
several members of the toll-like receptor family (Heil et al.,
2004; Rassa et al., 2002). Immune stimulation of newborn mice
may be a distinguishing feature from models of spontaneous B-
lymphoma development following the activation of endogenous
retroviruses. In support of this possibility, we recently reported
that the interferon response gene Icsbp/Irf8, which has never
been identified as a common insertion site in spontaneous B-
lymphomas, is a common insertion site in the models reported
in the present manuscript (Ma et al., 2006).
Because of the cohort sizes, even small differences in
latency periods among the mutants could be determined as
significant in some cases, whereas the latency periods to
disease induction by Akv and Akv1–99 were indistinguish-
able. Some enhancer mutants with alterations of a single
transcription factor motif (1–99mRunx, 1–99mGR, 1–
99mEgre, 1–99mEa/s) or two motifs (1–99mRunx+mGR)
induced disease with slightly shorter latency periods than their
parental Akv1–99 virus. We have no good explanation for
this, but note that mutants with alterations in two motifs were
associated with slightly longer latency periods than their
corresponding single site mutants. Except for the frequent
deletion of one of the two 99-bp enhancer copies in Akv-
induced tumors, all viral enhancer sequences were stably
maintained in vivo, reflecting that there is no strong selection
for reversion or second-site alterations towards more rapid
tumor development. Such changes have been extensively
found in T-lymphomagenic viruses with disease-attenuating
enhancer mutations of e.g. the Runx site (Ethelberg et al.,
1997a; Martiney et al., 1999; Morrison et al., 1995; Sørensen
et al., 2004). Hence, our present findings support the notion
that key sites of the enhancer are not critical for the latency to
disease induction in the Akv-based tumor models. Likewise,
in our previous work, we found that mutation of one or both
NF1 sites in Akv1–99 had no effect on latency to disease
induction (Sørensen et al., 2005).
Interestingly, mutations of the proviral enhancer caused a
shift in disease specificity independent of the latency periods to
disease induction. Akv induced about equal incidences of the
three major classes of tumors, FBLs at the germinal center
stage, DLBCLs at the more mature post-germinal center stage
and tumors of the fully mature plasma cell stage, plus a few
cases of tumors of other stages (splenic marginal zone
lymphomas and small B-cell lymphomas). For Akv1–99,
which lacks the duplication of the 99-bp enhancer, the pattern
of disease induction was shifted to few FBLs, 19% DLBCLs
and 77% plasma cell proliferations. This shift was even more
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proliferations constituted 95–100% of all cases. These findings
indicate that the preferential induction of mature B-cell tumor
types (particularly DLBCL and FBL) prior to the plasma cell
stage requires an intact Akv enhancer. Our results may further
suggest that the development of plasma cell proliferations
(plasmacytomas) is less dependent or independent of viral
enhancer strength, or possibly even favored by a weakened
enhancer. Consistent with this, we have previously found that
Akv1–99 transient enhancer activity is more than 2-fold lower
than that of wildtype Akv in an early B-cell line (NALM6),
whereas deletion of one 99-bp enhancer repeat has no effect on
enhancer activity in fully differentiated MPC11 plasmacytoma
cells (Lovmand et al., 1998; Sørensen et al., 2005).
Although the overall disease patterns induced by the
enhancer mutants in inbred NMRI were very similar, minor
differences in the presence or absence of LCCs and in the
frequency of detectable Ig rearrangements suggested that the
Runx site contributes the most and the Ets site the least to
Akv1–99 pathogenic potency. We note that transient enhancer
activities of 1–99mEts and 1–99mRunx were very similar in all
four cell lines tested (Table 1), despite the small difference in
disease induction patterns. The most likely explanation for this
is the usage of only a limited number of representative cell lines
in this study. The cell lines may not truly reflect the target cell
type(s) of viral infection in vivo during a complex multi-step
tumor induction process. Retrospectively, due to its broader
disease specificity in inbred NMRI mice, it is likely that Akv
would have provided a better background than Akv1–99 for
read-outs of possible differential effects of individual binding
site mutations.
The transcriptional enhancer may exert its role in the
specificity of disease induction through an effect on viralFig. 5. Dual effects of immune-stimulatory events and insertional mutagenesis in wi
follicular B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; PCP, plasma cexpression and/or replication in a given tissue, through its
ability to deregulate the expression of host genes by insertional
mutagenesis, or by a combination of the two. We know that
insertional mutagenesis is involved in disease induction by
exogenous Akv-type viruses since common insertion sites have
been identified in tumors of random-bred (Martin-Hernandez
et al., 2001; Martin-Hernandez et al., 2006) and inbred NMRI
mice (Ma et al., 2006, and unpublished). We recently reported
that Akv and Akv1–99 proviruses in tumors differed by their
overall positions relative to host transcription units (Martin-
Hernandez et al., 2006), suggesting that the proviral enhancer
influences the specific pattern of insertional mutagenesis in a
given tumor model. One interesting possibility is that the
unimpaired Akv enhancer is a more potent insertional activator
of e.g. stage-specific transcription factor genes, which may
serve to restrict differentiation along the B-cell lineage. The
enhancer mutants may be weaker in such activation and
function by a somewhat different register of insertional
mutations that allow the normal differentiation path for
activated B cells to plasma cells. In fact, the plasma cells in
the tumors may be the progeny of less differentiated tumor stem
cells (Wang and Dick, 2005). Further analysis of proviral
insertions may help elucidate the potential influence of
mutations that restrict differentiation.
Our interpretation of the combined contributions from
immune stimulation and insertional mutagenesis is shown in
Fig. 5. We propose that intraperitoneal injection of viral
supernatant into newborn mice activates an innate and/or
specific immune response that leads to a polyclonal expansion
of early B cells. The inbred NMRI model used in the present
work may be particularly rapid and often present with
polyclonal tumors because the immunostimulatory component
is strong in this strain. The stimulated cells may be a furtherldtype and enhancer mutated Akv-induced disease in inbred NMRI mice. FBL,
ell proliferation; PCT, plasmacytoma. See text for further description.
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the progenitor or more mature stage may affect the proliferative
ability or survival of the cells, as well as regulatory genes that
control differentiation. Dual contributions from mutations that
block differentiation and mutations that promote cell cycling
and survival are well-known from human leukemias (Steffen et
al., 2005). To explain the differences in disease specificity of
wildtype and enhancer mutated viruses, we propose that the
immunostimulatory and proliferative components may be
similar for all viruses, while proviruses with an impaired
enhancer may be less potent in activating host transcription
factors or other stage-specific genes that block differentiation.
Using random-bred NMRI mice, we have previously found
highly similar tumor induction patterns for Akv and Akv1–99
with predominant induction of mature B-cell lymphomas and
no plasmacytomas (Lovmand et al., 1998). This suggests that
different mechanisms of viral disease induction exist in the two
NMRI strains. The absence of plasmacytoma induction by Akv
and Akv1–99 in random-bred NMRI mice may be explained by
lack of a strong immunostimulatory component in this strain,
the lack of which may also favor induction of B-cell tumor types
prior to the fully differentiated stage. A reduced contribution
from an immunostimulatory component in the random-bred
NMRI strain may also explain the longer latency period to
disease induction as well as the appearance of clear clonal Ig
rearrangements in tumors of this strain. Moreover, mouse strain
specific integration site patterns of Akv and Akv1–99 may
influence disease induction in random-bred versus inbred
NMRI mice.
Finally, we note that the proposed model and the mor-
phological spectrum of the virus-induced tumors in inbred
NMRI mice are remarkably similar to those described for
human post-transplant lymphoproliferative disorders. These
lesions are characterized by an early antigen-driven, usually
polyclonal, plasma cell proliferation, which may later become
polymorphic (can be poly-, oligo- or monoclonal) and
eventually progress to DLBCL or less often plasmacytoma
(Jaffe et al., 2001; Lacasce, 2006). Accumulation of transloca-
tions or other types of mutations associated with progression of
this disease in man may be functionally comparable to
mutagenesis by provirus insertion in the murine models.
A superimposed activity of polyclonal stimulation and
insertional mutagenesis has been found in other models of
retrovirus-induced disease. The spleen focus-forming virus of
the Friend complex stimulates proliferation of erythroblasts,
which may be further subject to insertional mutagenesis by the
Friend helper virus, causing mono- or oligoclonal erythroleu-
kemia (Ben-David and Bernstein, 1991). Moreover, in an early
step of Moloney MLV-induced lymphomagenesis, extramedul-
lary hematopoiesis leads to increased progenitor cell popula-
tions of multiple lineages that are the targets of proviral
insertional mutagenesis (Fan, 1997). In murine acquired
immunodeficiency syndrome, a somewhat different model
system, a defective MLV is known to induce a polyclonal B-
cell expansion that in rare cases develop into oligoclonal B-
lymphomas through proviral insertional mutagenesis (Huang et
al., 1995). Hence, the overall outcome of a given MLVoncogenesis model may depend on the proliferative capability
of polyclonally stimulated cells as well as the outgrowth of
individual transformed cell clones. Future work should
investigate in more detail the mechanisms of Akv disease
induction in the inbred NMRI mouse model, e.g. by using
genetically modified mice with disabled immune response, as
well as by examining in detail the contributions of viral
infection, replication and gene expression at both early and later
stages of disease development.
Materials and methods
Cell culture
The murine MPC11 plasmacytoma B-cell line, NALM6
human pre-B cells, L691 murine T-lymphoma cells and NIH
3T3 murine fibroblasts were grown as described earlier
(Ethelberg et al., 1997a; Sørensen et al., 2005).
Plasmids
The plasmids pAkv6-cat and pAkv1–99-cat contain the
complete proviral LTR of Akv and Akv1–99, respectively, to
drive expression of a chloramphenicol acetyl transferase (CAT)
reporter gene (Lovmand et al., 1998). Mutations in individual
transcription factor binding sites of the Akv1–99 LTR region in
pAkv1–99-cat were introduced by PCR-based mutagenesis
using a 2-step overlap extension procedure. Two partially
overlapping Akv1–99 LTR fragments with specific point
mutations were generated with primer P1(akv) (5′-CCAGC-
TAACTGCAGTAACGCCATTT TGC-3′) plus mutPrimerX-
reverse and primer P2(akv)-reverse (5′-ATACACGGGTACCC-
GG GCGACTCAGTCT-3′) plus mutPrimerX-forward, respec-
tively (all mutPrimerX sequences are available upon request).
Next, these fragments were extended and PCR amplified using
primers P1(akv) and P2(akv)-rev. Double mutants were
generated using single site mutants as template for PCR-based
mutagenesis. The mutated PCR products were cut with PstI and
KpnI and cloned into pAkv6-cat, producing the mutant CAT
expression vectors p1–99mEts-cat, p1–99mRunx-cat, p1–
99mGR-cat, p1–99mEgre-cat, p1–99mEa/s-cat, p1–99mRunx
+mGR-cat, p1–99mRunx+mEgre-cat, p1–99mGR+mEa/s-cat
and p1–99mEgre+mEa/s-cat. The proviral clones of Akv and
Akv1–99 contain the entire viral genome with only one LTR
(Lovmand et al., 1998). Nine different Akv1–99 proviral
plasmids with mutations in transcription factor binding motifs
in the LTR region were generated by replacing a PvuI–PvuI
fragment from the proviral clone of Akv with the equivalent
PvuI–PvuI fragment from each of the mutated Akv1–99 CAT
expression plasmids.
Virus stocks and animal experiments
The generation of wildtype Akv and Akv1–99 virus stocks
has been described earlier (Lovmand et al., 1998). Infectious
mutant viruses were produced by transfecting NIH 3T3 cells
with concatemerized PstI–PstI fragments from mutant Akv1–
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monitored by measuring reverse transcriptase activity in cell
culture supernatants (Hallberg et al., 1991), and the integrity of
proviral LTR regions with introduced point mutations verified
by PCR and sequencing (see below). Infectious virus particles
were injected intraperitoneally into newborn inbred NMRI
mice, as earlier described in details (Sørensen et al., 2004).
Control mice of the same colony were mock-injected with
0.1 mL complete medium. The animals were monitored 5 days
per week for a 9-month observation period. Mice were
sacrificed and autopsied when showing signs of illness or
tumor development (mainly palpable splenomegaly and/or
lymphadenopathy, and fatigue). Tumor development was
diagnosed on the basis of grossly enlarged lymphoid organs
after having reached the size described earlier, which is
compatible with lymphoma (Schmidt et al., 1984). Lymphoid
tumor tissues and the liver were dissected, stored frozen
(−80 °C) and/or fixed in formalin for further analysis. Statistical
analysis was carried out using the log-rank test.
Histopathological examination and immunohistochemical
analysis
Formalin-fixed, paraffin-embedded sections of lymph nodes,
thymus, spleen and liver were stained with hematoxylin and
eosin (H&E), and when indicated with Giemsa, or PAS. Tumors
were classified according to the Bethesda proposals for
classification of murine hematopoietic neoplasms (Kogan et
al., 2002; Morse et al., 2002). Immunohistochemistry (IHC)
was performed on an automated immunostainer (Ventana
Medical System, Inc.; AZ, USA), according to the protocol
provided by the company with minor modifications. After
deparaffination and rehydration, the slides were placed in a
microwave pressure cooker in 0.01 M citrate buffer (pH 6.0),
containing 0.1% Tween-20 and heated in a microwave oven at
maximum power for 30 min. After cooling in Tris-buffered
saline, the sections were incubated with 3% goat or rabbit serum
for 20 min. The antibody panel used included CD3, CD79acy,
TdT (Dako, Germany), CD138, B220/CD45R (BD Bioscience,
NJ, USA), Ki-67 and MPO (DCS, Germany). Appropriate
positive controls were used to confirm the adequacy of the
staining.
Southern blotting hybridization and DNA probes
Genomic DNAwas purified from frozen tumor tissues using
the DNeasy tissue kit (Qiagen). Southern blotting, hybridization
procedures and DNA probes have been described in details
previously (Lovmand et al., 1998; Sørensen et al., 2004). In
brief, 15 μg of HindIII digested genomic tumor DNA was
separated on 0.8% agarose gels, blotted onto nylon membranes
and hybridized with 32P random priming labeled probes specific
for the immunoglobulin kappa (Igκ) light chain gene, the
immunoglobulin heavy (IgH) chain gene (probe named IgH-J11)
and the T-cell receptor β-J1 and -J2 (TCRβ-J1 and-J2) joining
region genes. The IgH-J11 probe was used also with EcoRI
digested DNA. An ecotropic viral envelope (env) gene-specificprobe (Lovmand et al., 1998) was hybridized to genomic DNA
digested with HindIII or EcoRI (no cutting sites in Akv/Akv1–
99) or with PstI or EcoRV (generate an internal env containing
Akv/Akv1–99 provirus fragment).
Transfection and reporter assays
The DEAE-dextran method (Ethelberg et al., 1997a) was
used to transfect MPC11, NALM6 and L691 cells, whereas NIH
3T3 cells were transfected by calcium phosphate-mediated
precipitation (Ethelberg et al., 1997a). Each transfection
included 2 μg/3 μg/4 μg (NIH 3T3/NALM6/L691 and
MPC11) CAT expression vector together with 1.5 μg/2 μg
(NIH 3T3/NALM6, L691 and MPC11) pRSV-luc internal
control plasmid to correct for different transfection efficiencies,
and 8 μg/10 μg/11.5 μg (NALM6/L691 and MPC11/NIH 3T3)
pUC19 carrier DNA. All transfections were done in duplicate
and repeated 2 to 8 times, unless stated otherwise. CAT and
luciferase activities were measured in whole cell extracts
prepared 48 h after transfection by repeated cycles of freeze/
thawing (Ethelberg et al., 1997a).
PCR and DNA sequencing
Proviral U3 enhancer–promoter regions were PCR amplified
from genomic tumor DNA samples using a primer (440, 5′-
TTCATAAGGCTTAGCCAGCTAAC TGCAG-3′) in the 5′
end of the U3 region in combination either with a primer (2620;
5′-GAATTCGATATCGATCCCCGGTCATCTGGG-3′)
located ca. 60 bp downstream of the enhancer, i.e. overlapping
the Ea/s site, or in cases with this site mutated (1–99mEa/s, 1–
99mGR+mEa/s and 1–99mEgre+mEa/s) a primer located in the
5′ untranslated region (1112akv; 5′-GTAGATGCCGGCACA-
CACACACACACGCA-3′). PCR products were analyzed by
agarose gel electrophoresis, purified and sequenced, as
described previously (Sørensen et al., 2005).
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